ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod ® 5 App for iPhone is now compatible with the ...

Insulet Corp.’s PODD groundbreaking Omnipod 5 Automated Insulin Delivery (“AID”) system (Omnipod 5) received the FDA’s approval for use by type 2 diabetes patients (ages 18 years and above). The news ...

Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet’s groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from ...

First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...